Loading…
Ken GriffinHeld
Citadel Advisors · Q2 2026
$467.52K
14.89K shares · 0.0% of portfolio
Phibro Animal Health Corp
Phibro Animal Health Corp (PAHC) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Teaneck, United States and has 2,605 employees. The company is worth $1.62B and trades at 16.4x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $1.52B in fiscal 2026, up 17.1% from the year before. Net income was $99.72M. The share price is 33.7% below its 52-week high of $60.08. It pays a dividend yielding 1.21%. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $29.41M. In that quarter, 1 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +98.2% over 5Y.
today you would have $2,004.15▲ +100.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 13 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $38.82 | $37.36 | $21.00 | $11.58 | $13.41 | $20.42 | $19.42 | $24.83 | $32.16 | $33.50 | $29.30 | $30.13 | $31.55 | |
| P/E | 18.4x | 16.0x | 31.4x | 350.0x | 14.3x | 11.1x | 15.2x | 23.4x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 12.6% a year plus a 1.2% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 18.4 across this company’s own years on record.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZBIOZenas BioPharma, Inc. | $24.84 | — | 6.4x | 0.00% | -199.04% | $1.62B |
| CMPSCOMPASS Pathways plc | $11.63 | — | 18.7x | 0.00% | -319.07% | $1.61B |
| KMTSKestra Medical Technologies Ltd | $27.24 | — | 7.3x | 0.00% | -73.73% | $1.62B |
| QUREuniQure N.V. | $23.11 |
| 18.4x |
| 20.0x |
| 20.8x |
| 14.2x |
| 20.0x |
| — |
| P/S | 0.8x | 1.0x | 1.2x | 0.8x | 0.5x | 0.6x | 1.0x | 1.0x | 0.0x | 0.0x | 0.0x | 0.0x | 1.6x | 1.5x |
| P/B | 3.3x | 4.1x | 5.3x | 3.3x | 1.7x | 2.1x | 3.5x | 4.2x | 0.0x | 0.0x | 0.0x | 0.0x | 40.5x | 67.0x |
| EPS | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 | $0.83 | $1.35 | $1.61 | $1.61 | $2.07 | $1.51 | -$0.10 |
| Dividend yield | 1.37% | 0.93% | 1.28% | 2.29% | 4.15% | 3.58% | 2.35% | 2.47% | 1.93% | 1.31% | 1.19% | 1.37% | 1.33% | 0.63% |
| Payout | 35.69% | 14.81% | 40.34% | 800.00% | 59.26% | 39.67% | 35.82% | 57.83% | 35.56% | 26.09% | 24.84% | 19.32% | 26.49% | — |
| Profit margin | 6.53% | 6.57% | 3.72% | 0.24% | 3.33% | 5.22% | 6.53% | 4.19% | 6.61% | 7.91% | 8.45% | 11.01% | 8.05% | -0.45% |
| ROE | 22.80% | 25.87% | 16.89% | 0.94% | 11.54% | 18.74% | 22.80% | 17.83% | 25.33% | 35.08% | 42.75% | 91.43% | 203.46% | -20.64% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 2 families.
Room for errors in the reported numbers.
+35.6% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 4.9x |
| 0.00% |
| -157.61% |
| $1.6B |
| NVAXNovavax Inc | $9.99 | — | — | 0.00% | — | $1.65B |
| NUVBNuvation Bio Inc. | $4.70 | — | 6.5x | 0.00% | -47.81% | $1.65B |